Department of Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.
Department of Gynaecology and Obstetrics, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.
Biomol Biomed. 2024 Mar 7;24(4):753-763. doi: 10.17305/bb.2024.10114.
Previous studies have reported mixed results regarding the relationship between serum copeptin levels and gestational diabetes mellitus (GDM) risk. To address inconsistencies in prior research, this meta-analysis examines the potential link between serum copeptin levels and the risk of developing GDM. Our objective was to comprehensively evaluate this association. We systematically reviewed observational studies from Medline, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases up to October 15, 2023, employing a random-effects model to integrate the data while considering heterogeneity. This analysis incorporated 10 studies comprising 625 women with GDM and 1212 healthy pregnant controls. Our findings showed no significant difference in serum copeptin levels between women with GDM and those without (standardized mean difference [SMD] 0.01, 95% confidence interval [CI] -0.22 to 0.24, P = 0.92, I2 = 75%). Univariate meta-analysis indicated a positive correlation between the body mass index (BMI) of the participants and the outcomes (coefficient = 0.11, P = 0.002). Further subgroup analysis demonstrated that women with a mean BMI ≥ 26 kg/m2 and GDM had significantly higher serum copeptin levels compared to their non-GDM counterparts (SMD 0.31, 95% CI 0.05 to 0.57, P = 0.02, I2 = 46%). Conversely, no difference was observed in women with a BMI < 26 kg/m2 (SMD -0.23, 95% CI -0.37 to-0.09, P = 0.002, I2 = 0%, P for subgroup difference = 0.003). Variables, such as the country of study, maternal age, the timing of blood sampling, copeptin measurement methods, or GDM diagnostic criteria did not significantly affect the results. In summary, the association between serum copeptin levels and GDM risk is influenced by the BMI of pregnant women, indicating that elevated serum copeptin might be linked to GDM in individuals with a BMI ≥ 26 kg/m2.
先前的研究报告了血清 copeptin 水平与妊娠糖尿病（GDM）风险之间的关系存在差异。为了解决先前研究中的不一致性，本荟萃分析研究了血清 copeptin 水平与发生 GDM 的风险之间的潜在关联。我们的目标是全面评估这种关联。我们系统地检索了 Medline、Web of Science、Embase、万方和中国知网（CNKI）数据库中的观察性研究，截至 2023 年 10 月 15 日，使用随机效应模型整合数据，并考虑异质性。该分析纳入了 10 项研究，共纳入了 625 名 GDM 妇女和 1212 名健康孕妇对照。我们的研究结果显示，GDM 妇女与非 GDM 妇女的血清 copeptin 水平无显著差异（标准化均数差 [SMD] 0.01，95%置信区间 [CI] -0.22 至 0.24，P = 0.92，I2 = 75%）。单变量荟萃分析表明，参与者的体重指数（BMI）与结果之间存在正相关（系数 = 0.11，P = 0.002）。进一步的亚组分析表明，BMI 平均值≥26 kg/m2 的 GDM 妇女与非 GDM 妇女相比，血清 copeptin 水平显著升高（SMD 0.31，95%CI 0.05 至 0.57，P = 0.02，I2 = 46%）。然而，BMI < 26 kg/m2 的妇女之间无差异（SMD -0.23，95%CI -0.37 至-0.09，P = 0.002，I2 = 0%，P 亚组差异 = 0.003）。研究国家、产妇年龄、采血时间、copeptin 测量方法或 GDM 诊断标准等变量均未显著影响结果。综上所述，血清 copeptin 水平与 GDM 风险之间的关联受孕妇 BMI 的影响，提示 BMI≥26 kg/m2 的个体中，血清 copeptin 水平升高可能与 GDM 有关。
